Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:bioRxiv
Asıl Yazarlar: Wang, Xuanting, Sacramento, Carolina Q., Jockusch, Steffen, Chaves, Otávio Augusto, Tao, Chuanjuan, Fintelman-Rodrigues, Natalia, Chien, Minchen, Temerozo, Jairo R., Li, Xiaoxu, Kumar, Shiv, Xie, Wei, Patel, Dinshaw J., Meyer, Cindy, Garzia, Aitor, Tuschl, Thomas, Bozza, Patrícia T., Russo, James J., Souza, Thiago Moreno L., Ju, Jingyue
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Cold Spring Harbor Laboratory 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312893/
https://ncbi.nlm.nih.gov/pubmed/34312622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.07.21.453274
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller